Rockwell Medical

307 articles with Rockwell Medical

• Rockwell Medical, Inc. Provides Third Quarter 2020 Financial and Operational Update

  11/9/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended September 30, 2020.

• Rockwell Medical to Report Third Quarter 2020 Financial and Operating Results on November 9, 2020

  10/27/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 9, 2020, at 4:30 p.m.

• Rockwell Medical, Inc. Announces Presentations at the American Society of Nephrology Virtual Kidney Week 2020

  10/13/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that two abstracts have been accepted for poster presentation at the American Society of Nephrology (ASN) Virtual Kidney Week 2020, which will occur from October 20 to 25, 2020.

• Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform

  9/24/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, earlier today concluded its Management and Key Opinion Leader (KOL) conference call and webcast to discuss potential novel indications for its ferric pyrophosphate citrate (FPC) platform.

• Rockwell Medical Announces $35.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  9/23/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has entered into securities purchase agreements with several healthcare-focused and other institutional investors to purchase 23,178,809 of its shares of common stock

• 

  BioSpace Movers & Shakers, Sept. 18

  9/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer

  9/15/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the appointment of Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer (“CFO”) and Chief Business Officer (“CBO”), effective today, September 15, 2020

• Rockwell Medical to Host Conference Call and Webcast with Management and Key Opinion Leaders to Discuss Potential Novel Indications for Its FPC PlatformCall and Webcast Scheduled for September 24, 2020, at 4:30 p.m. Eastern

  9/9/2020

  Rockwell Medical, Inc. announced it will host a conference call and webcast on Thursday, September 24, 2020, at 4:30 p.m. ET to discuss potential novel applications of ferric pyrophosphate citrate, the active pharmaceutical ingredient in Triferic®, for the treatment of iron deficiency anemia in patients undergoing home infusion therapy and iron deficiency in patients with acute heart failure.

• Rockwell Medical Enters into Exclusive License Agreement with Jeil Pharmaceutical Co., Ltd., for the Rights to Commercialize Triferic® in South Korea

  9/9/2020

  Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually

• Rockwell Medical, Inc. to Present at Upcoming September 2020 Investor Conferences

  9/8/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced the Rockwell Medical executive management team will present at two upcoming investor conferences in September

• Rockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update

  8/10/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended June 30, 2020.

• Rockwell Medical to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

  8/3/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced that it will host a conference call on Monday, August 10, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2020, and recent operational highlights.

• Rockwell Medical, Inc. Appoints Dr. Allen R. Nissenson to Board of Directors

  6/10/2020

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the appointment of industry leader and renowned authority on kidney disease, Allen R. Nissenson, M.D., F.A.C.P., to its Board of Directors

• Rockwell Medical, Inc. Files New Drug Submission with Health Canada for Marketing Approval of Triferic® AVNU™

  5/26/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced the filing of a New Drug Submission with Health Canada for Triferic AVNU.

• Rockwell Medical, Inc. Provides First Quarter 2020 Financial and Operational Update and Top-line Real-World Triferic Data

  5/11/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, reported financial results and a business update for quarter ended March 31, 2020.

• 

  BioSpace Movers & Shakers, April 24

  4/24/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers.

• Rockwell Medical, Inc. Appoints Russell H. Ellison, M.D., M.Sc., as President and Chief Executive OfficerCompany to Host Q1 2020 Earnings and Corporate Update Call and Webcast on May 11, 2020, at 4:30 p.m. ET

  4/20/2020

  WIXOM, Mich., April 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that the Board of Directors has appointed Russell H. Ellison, M.D., M.Sc. as President and Chief Executive Officer, effective immediately. Dr. Ellison will continue to serve as a member of the Company’s Board. Stuart Paul has resi

• Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors

  3/31/2020

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced the appointment of pharmaceutical industry leader Robert S. Radie to its Board of Directors, effective March 31, 2020..

• Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients

  3/27/2020

  Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its New Drug Application (“NDA”) for its intravenous formulation of Triferic, Triferic AVNU.

• 

  FDA Action Alert: Celgene, Zogenix, Heron, Intercept, IntelGenx and Rockwell

  3/23/2020

  The U.S. Food and Drug Administration has a busy week of possible drug approvals on its calendar. Here’s a look.